Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515099 · ClinicalTrials.gov registry record · Phase 2
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00515099 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 58 participants.
The verdict
NCT00515099, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Antithymocyte globulin (e.g., Thymoglobulin®) is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether antithymocyte globulin (ATG) treatment can halt the progression of newly diagnosed type 1 diabetes when given within 12 weeks of disease diagnosis.
Interventions
- DRUG Placebo
- DRUG Antithymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2007-08 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515099
The ClinicalTrials.gov registry entry for NCT00515099 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00515099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515099 about?
NCT00515099 is a clinical study titled "Study of Antithymocyte Globulin for Treatment of New-onset T1DM". Antithymocyte globulin (e.g., Thymoglobulin®) is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether antithymocyte globulin (ATG) treatment can halt the progression of newly diagnosed type 1 diabetes when given with...
What is the current status of trial NCT00515099?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2007-08. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00515099?
The interventions under investigation include: Placebo (DRUG), Antithymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00515099?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.